mTOR inhibition in management of advanced breast cancer
Abstract: The mTOR pathway is becoming increasingly important in several cancers including breast cancer. This review will focus on the role of its inhibition in the management of advanced breast cancer.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
mTOR inhibition in management of advanced breast cancer ; volume:33 ; number:02 ; year:2012 ; pages:89-94
Indian journal of medical & paediatric oncology ; 33, Heft 02 (2012), 89-94
- Beteiligte Personen und Organisationen
-
Nag, Shona
- DOI
-
10.4103/0971-5851.99737
- URN
-
urn:nbn:de:101:1-2022060210104633518508
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nag, Shona
Ähnliche Objekte (12)
Brain-restricted mTOR inhibition with binary pharmacology
Nutritional and pharmacological modes of mTOR inhibition
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers
Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction
Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy
Clinical development of mTOR inhibitors in breast cancer
mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Lysosomal activation and mTOR inhibition synergize to kill myeloid leukemia cells
mTOR Inhibition durch Aspirin - antiproliferative Effekte auf neuroendokrine Tumorzellen in vitro
Brain-restricted mTOR inhibition with binary pharmacology
Nutritional and pharmacological modes of mTOR inhibition
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers
Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction
Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy
Clinical development of mTOR inhibitors in breast cancer
mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Lysosomal activation and mTOR inhibition synergize to kill myeloid leukemia cells
mTOR Inhibition durch Aspirin - antiproliferative Effekte auf neuroendokrine Tumorzellen in vitro
Brain-restricted mTOR inhibition with binary pharmacology
Nutritional and pharmacological modes of mTOR inhibition
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers
Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction
Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy
Clinical development of mTOR inhibitors in breast cancer
mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Lysosomal activation and mTOR inhibition synergize to kill myeloid leukemia cells